Patents Issued in February 16, 2017
  • TABLETTABLE CHEWING GUMS
    Publication number: 20170042879
    Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 16, 2017
    Inventors: Markus RUDOLPH, Giovanna MARZANO, Isabelle RAULT
  • Method of Treating Lung Adenocarcinoma
    Publication number: 20170042880
    Abstract: This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGFR2, and ROS1 which is a compound of Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Inventors: Dana T. Aftab, Peiwen Yu
  • TREATMENT OF H-RAS-DRIVEN TUMORS
    Publication number: 20170042881
    Abstract: The present disclosure describes a compositions and methods for treatment of Hras-driven cancers. Administration of a farnesyltransferase inhibitor, for example, tipifarnib, alone or in combination with a MEK inhibitor can reduce tumor size and tumor growth in cancers such as poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC).
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: James A. FAGIN, Jeffrey A. KNAUF, Brian R. UNTCH
  • Selective Opioid Compounds
    Publication number: 20170042882
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 16, 2017
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
  • Methods for Detecting and Treating Rhinovirus Infection
    Publication number: 20170042883
    Abstract: The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 16, 2017
    Inventors: Robert Joseph Isfort, Xiaoyan Angela QU
  • LIQUID BUPRENORPHINE FORMULATIONS
    Publication number: 20170042884
    Abstract: The invention provides liquid formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides liquid formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering liquid formulations containing buprenorphine or a combination of buprenorphine and naloxone, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Kiran P. Amancha, Chandeshwari S. Chilampalli, Venkat R. Goskonda
  • Treating Pain In Patients With Hepatic Impairment
    Publication number: 20170042885
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMA
    Publication number: 20170042886
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: August 22, 2016
    Publication date: February 16, 2017
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins University
    Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael J. Handley, Avadhut JOSHI, Gregory J. RIGGINS, Theodore M. TARASOW
  • Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
    Publication number: 20170042887
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 16, 2017
    Applicants: OTSUKA PHARMACEUTICAL. CO., LTD., H. LUNDBECK A/S
    Inventors: Kenji MAEDA, Mai NAKAMURA
  • GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
    Publication number: 20170042888
    Abstract: The invention is related to compounds, which are GlyT1 inhibitors, for use in the treatment of hematological disorders, in particular for use in the treatment of sickle cell disease and thalassemia, or for the treatment of patients with iron overload syndromes, such as hereditary hemochromatosis.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Daniela Alberati, Annette Koerner, Emmanuel Pinard, Michael Winter
  • AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170042889
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • METHODS OF REDUCING DECLINE IN VITAL CAPACITY
    Publication number: 20170042890
    Abstract: Provided herein are compositions and methods for reducing the decline in vital capacity in a subject by administering to the subject a skeletal muscle troponin activator. Also provided are compositions and methods for reducing respiratory decline in a subject, as measured by slow vital capacity (SVC), by administering to the subject a skeletal muscle troponin activator.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 16, 2017
    Inventors: Jeremy M. SHEFNER, Andrew A. WOLFF, Fady MALIK, Jinsy A. ANDREWS
  • AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER
    Publication number: 20170042891
    Abstract: This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective amount of one or more chemotherapeutic agents.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 16, 2017
    Inventors: Yasumichi Hitoshi, Sacha Holland, Donald G. Payan
  • HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170042892
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: Celia Dominguez, Perla Breccia, Christopher A. Luckhurst, Roland W. Bürli, Andrew J. Stott
  • USE OF CASEIN KINASE I INHIBITORS FOR DEPLETING STEM CELLS
    Publication number: 20170042893
    Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a Casein kinase I alpha (CKIalpha) inhibitor, wherein the cancer is not associated with an Adenomatous polyposis coli (APC) mutation. Additional uses of CKI inhibitors are also disclosed.
    Type: Application
    Filed: February 3, 2015
    Publication date: February 16, 2017
    Inventors: Yinon BEN-NERIAH, Waleed MINZEL, Guy BRACHYA
  • Methods Of Treating Dyskinesia And Related Disorders
    Publication number: 20170042894
    Abstract: The present disclosure describes compounds and pharmaceutically acceptable salts, thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 16, 2017
    Inventors: John Ciallella, John Gruner, Andrew G. Reaume, Michael S. Saporito
  • Combination Treatment Comprising Administration of 2-Amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
    Publication number: 20170042895
    Abstract: The present invention is directed to the combined use of BACE1 inhibitor of Formula I and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive A? peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 16, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen
  • CERDULATINIB FOR TREATING MYELOMA
    Publication number: 20170042896
    Abstract: Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.
    Type: Application
    Filed: August 12, 2016
    Publication date: February 16, 2017
    Inventors: Gregory Coffey, Jiajia Feng
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042897
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 16, 2017
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS
    Publication number: 20170042898
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Applicants: HEMAQUEST PHARMACEUTICALS, INC., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ronald J. Berenson, Douglas V. Faller
  • Use of Tetrahydrobiopterine Derivatives in the Treatment and Nutrition of Patients With Amino Acid Metabolic Disorders
    Publication number: 20170042899
    Abstract: The invention relates to the use of tetrahydrobiopterine and the derivatives thereof in the production of a medicament to improve protein tolerance for the treatment of diseases arising from an amino acid metabolic disorder, e.g. hyperphenylalaninemia. The invention also relates to a composition which contains tetrahydrobiopterine or derivatives thereof in addition to a special mixture of amino acids. The invention can, for instance, be used as a food which is low in phenylalanine in the complete nutrition of hyperphenylalaninemic patients. Tests carried out within the text of said invention revealed that by treating the context of said invention revealed that by treating patients who had phenylalanine concentrations of more than 200 ?mol/l in their blood with tetrahydrobiopterine, it was possible to reduce the concentrations of phenylalanine by 37% to 92%.
    Type: Application
    Filed: July 15, 2016
    Publication date: February 16, 2017
    Inventors: Ania Muntau-Heger, Adelbert A. Roscher
  • PREVENTIVE AND/OR THERAPEUTIC AGENT OF IMMUNE DISEASE
    Publication number: 20170042900
    Abstract: Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R1 to R3, W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 16, 2017
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Fumihito HOSOI, Yoshinori Nakachi, Daisuke Kajiwara
  • METHODS AND COMPOSITIONS FOR INHIBITION OF POLYMERASE
    Publication number: 20170042901
    Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20170042902
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Topical Ophthalmic Formulations for the Treatment and Prevention of Migraine Headache
    Publication number: 20170042903
    Abstract: The present invention provides topical ophthalmic formulations comprising a combination of one or more antihistamine agents and optionally one or more vasculature modifying agents such as a ? adrenergic receptor antagonist. Also provided are methods of using the formulations of the invention for treating and/or preventing symptoms associated with migraine headache, and for reducing the frequency, severity and duration of migraine attacks.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 16, 2017
    Inventors: Mark B. Abelson, Matthew J. Chapin
  • METHODS FOR TREATING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20170042904
    Abstract: The present invention is directed to methods of treating T-ALL that involve administering an inhibitor of jumonji D3 (JMJD3) demethylase. Another embodiment of the invention relates to methods inhibiting T-ALL cell proliferation and/or survival that involves administering an inhibitor of jumonji D3 (JMJD3) demethylase to a population of T-ALL cells.
    Type: Application
    Filed: August 15, 2016
    Publication date: February 16, 2017
    Applicant: New York University
    Inventors: Iannis AIFANTIS, Panagiotis NTZIACHRISTOS
  • Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto
    Publication number: 20170042905
    Abstract: The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Inventors: Thota Ganesh, Jianxiong Jiang, Ray J. Dingledine
  • FATTY ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME
    Publication number: 20170042906
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY
    Publication number: 20170042907
    Abstract: Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X1. each of the two axial ligands has the formula —OC(?O)X1 wherein each X1 is independently substituted or unsubstituted phenyl or —C(—X2)(—X3)(—X4); each X2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl; each X3 is independently hydrogen, hydroxyl, alkyl, amino, —X5C(?O)R13 where X5 is NH or O, and R13 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or —OR14, where R14 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or together with X4 is (?O); and each X4 is independently hydrogen or together with X3 is (?O).
    Type: Application
    Filed: August 25, 2016
    Publication date: February 16, 2017
    Inventors: Jeffery L. KEENE, Otto F. SCHALL, Dennis P. RILEY
  • METHOD FOR TREATING GEOGRAPHIC ATROPHY ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
    Publication number: 20170042908
    Abstract: Disclosed is a method for treating geographic atrophy associated with age-related macular degeneration in a subject, which comprises administering a 15-keto-prostaglandin compound to the subject in need of the treatment. The 15-keto-prostaglandin compound such as Isopropyl Unoprostone is useful for treating geographic atrophy as well as for preventing vision loss caused by geographic atrophy.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 16, 2017
    Inventors: Fumio SHIRAGA, Chieko SHIRAGAMI, Yukihiko MASHIMA
  • NEURO-PROTECTIVE AGENTS AND USES THEREOF (As Amended)
    Publication number: 20170042909
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Application
    Filed: April 14, 2015
    Publication date: February 16, 2017
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY
    Publication number: 20170042910
    Abstract: This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl
  • PHARMACEUTICAL FORMULATIONS AND USES THEREOF IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
    Publication number: 20170042911
    Abstract: The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analog thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)). It further relates to the influence of the combination of testosterone or an analog thereof and a compound capable of at least in part inhibiting smooth muscle constriction, for example a compound capable of at least in part inhibiting the adrenergic tone. The invention further discloses other combinatorial therapies in the treatment of Female Sexual Dysfunction.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Applicant: EB IP LYBRIDO B.V.
    Inventors: Jan Johan Adriaan TUITEN, Johannes Martinus Maria BLOEMERS
  • PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
    Publication number: 20170042912
    Abstract: A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.
    Type: Application
    Filed: September 14, 2015
    Publication date: February 16, 2017
    Inventor: PO-LIANG CHEN
  • USE OF 2-METHYLENE-19-NOR-(20S)-1ALPHA,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM IN PATIENTS PREVIOUSLY TREATED WITH CALCIMIMETICS
    Publication number: 20170042913
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 16, 2017
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Osteoclast Inhibitors for Knee Conditions
    Publication number: 20170042914
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventor: Herriot Tabuteau
  • LPA RECEPTOR MODULATORS FOR BROWN FAT DIFFERENTIATION
    Publication number: 20170042915
    Abstract: Described herein is a method of increasing brown fat differentiation or increasing energy expenditure in a subject in need thereof, the method comprising administering to the subject an LPA receptor modulator, or a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, deuteride, N-oxide, stereoisomer, or isomer thereof.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 16, 2017
    Inventors: Matthew S. TREMBLAY, Nicole ALVAREZ, Weijun SHEN, Andrew TO
  • ANIMAL TISSUE COLONIZATION AND TREATMENT OF INFECTION
    Publication number: 20170042916
    Abstract: An antimicrobial composition and methods of use are provided. This antimicrobial composition includes a water-soluble organosilane (3-(trihydroxysilyl) propyldimethyloctadecyl ammonium chloride) and additional adjuvant compounds, including anti-inflammatory medications, antiseptics, transdermal penetrants, nutrients and/or buffers, generally to be applied in liquid form to penetrate and kill biofilms that are infecting living vertebrates. The methods include topically treating an infection by penetrating and disrupting an existing biofilm and killing cells therein and killing any persister cells that, through degrees of dormancy or otherwise, have escaped being killed during the initial application of the antimicrobial composition.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: Carl Hilliard, William R. Cast
  • SUBSTITUTED BICYCLIC COMPOUNDS
    Publication number: 20170042917
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Alaric J. Dyckman, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • METHOD OF IMPROVING SKILLS WITH A COMPOSITION COMPRISING NON-DIGESTIBLE SACCHARIDE
    Publication number: 20170042918
    Abstract: The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 16, 2017
    Inventors: Bernd STAHL, Jan KNOL
  • Analogs of N-Acetlyglucosamine and Uses Thereof
    Publication number: 20170042919
    Abstract: The present invention includes a novel method of treating or preventing a disease or disorder associated with low levels of branched N-glycans in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Inventors: Michael Demetriou, James Dennis, Ani Oganesyan
  • Guanosine as an Immune Potentiator Mediated Through Toll Receptors
    Publication number: 20170042920
    Abstract: Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of preventing and treating cancer and infection by administration of guanosine or pro-drugs of guanosine, or a precursor of guanosine are also disclosed. Compositions of guanosine or a pro-drug of guanosine or precursor of guanosine may be formulated as pharmaceutical dosage forms and components can be assembled as kits. Methods for activating TLRs with guanosine to enhance an immune response and to potentiate/augment antiviral, antibacterial or anticancer effects of other antiviral, anti-bacterial and anticancer therapeutic agents are also disclosed.
    Type: Application
    Filed: December 19, 2014
    Publication date: February 16, 2017
    Inventor: Shanta Bantia
  • METHOD FOR TREATING HIV
    Publication number: 20170042921
    Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 16, 2017
    Applicant: Enzo Therapeutics, Inc.
    Inventors: Yaron ILAN, Maya Margalit, Ari Zimran, Elazar Rabbani, Dean L. Engelhardt
  • SITAGLIPTIN TANNATE COMPLEX
    Publication number: 20170042922
    Abstract: The present invention provides for a sitagliptin tannate complex or a pharmaceutical compositions or a pharmaceutically acceptable intermediates comprising said complex. This invention also relates to a processes to prepare the sitagliptin tannate complex as well as to methods of using the sitagliptin tannate complex to treat diabetes, obesity and high blood pressure.
    Type: Application
    Filed: April 13, 2015
    Publication date: February 16, 2017
    Inventors: Wycliffe Omwancha, Rubi Burlage
  • REDUCED TOXICITY MOLECULAR CONJUGATES OF ANTI-FUNGAL AGENTS
    Publication number: 20170042923
    Abstract: Compositions, compounds and methods are described for addressing both toxicity of membrane disruptive anti-microbial agents as well as poor transport of such agents across the blood-brain-barrier (BBB) via the use of molecular appendages including one or more facial amphiphiles. These molecules have in vitro anti-fungal activity that is very similar to that of the native drug but with hemolytic activity and toxicity towards mammalian cells that is greatly reduced.
    Type: Application
    Filed: August 10, 2016
    Publication date: February 16, 2017
    Inventors: Steven L. Regen, Vaclav Janout, Yuming Yu
  • MUSCLE ATROPHY INHIBITOR CONTAINING QUERCETIN GLYCOSIDE
    Publication number: 20170042924
    Abstract: An object of the present invention is to provide a new muscle atrophy inhibitor comprising a component that is safely ingestible for a long time. It was found that glycosides of quercetin, a polyphenol present in plants, etc., have inhibitory activity on the expression of myostatin involved in muscle atrophy. This invention provides a new muscle atrophy inhibitor comprising a quercetin glycoside which is excellent in absorbability into the body and high in safety.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 16, 2017
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Yuta OTSUKA, Kahori EGAWA, Noriyuki KANZAKI
  • GLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20170042925
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: April 20, 2016
    Publication date: February 16, 2017
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • TREATING OCULAR NEOVASCULARIZATION
    Publication number: 20170042926
    Abstract: Methods of treating ocular neovascularization, e.g., associated with wet agerelated macular degeneration (AMD), using activators of AMP-activated protein kinase (AMPK) and/or of Phosphatase and tensin homolog deleted on chromosome 10 (PTEN).
    Type: Application
    Filed: January 2, 2015
    Publication date: February 16, 2017
    Inventors: Demetrios Vavvas, Joan W. Miller, Kimio Takeuchi
  • EFFECTIVE TREATMENT OF OVARIAN CANCER USING TRICIRIBINE AND RELATED COMPOUNDS
    Publication number: 20170042927
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Application
    Filed: July 25, 2016
    Publication date: February 16, 2017
    Inventor: Jin Q. CHENG
  • Edible Energy Composition
    Publication number: 20170042928
    Abstract: The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Applicant: International IP Holdings LLC
    Inventor: Manoj Bhargava